The data AI needs to
solve chronic disease

Mune's blood tests read thousands of biomarkers, so people with chronic disease can see what standard labs miss. Every test builds the dataset future diagnostics and therapies will learn from.

PDB 7S4S · SARS-CoV-2 RBD–Antibody ComplexAlphaFold learned from structures like this. Chronic disease has no such dataset yet.
Current Pipeline
Mune Mirror™
Launching soon
Long COVID Molecular Subtyping Test
In development

Your body already knows what's wrong. Today, medicine reads only a few of its signals at a time. AI has exceeded human capabilities in computer programming, mathematics, and even protein folding. We believe AI will also exceed humans in discovering diagnostic biomarkers and therapeutic targets. Every one of these breakthroughs had its training ground. ChatGPT had the internet to learn language. Anthropic and OpenAI had RL environments for coding and mathematics. AlphaFold had the Protein Data Bank, and solved a problem biology had been stuck on for decades. Chronic disease has no such training ground. The disease-specific, longitudinal biological data AI needs does not yet exist. We are building this training infrastructure for chronic disease, starting with long COVID. In the process, we help millions of chronically ill patients find answers.

Team

A proven team from
Stanford and Natera

Michael Snyder, PhD
Co-Founder
Director, Center for Genomics & Personalized Medicine, Stanford · co-founded 20 companies worth $6.8B combined, including Personalis
Jo Teichmann
Co-Founder & CEO
Five-time founder · thesis on AI diagnostics in the Snyder Lab
Team
Robyn Schlicher, PhD
Robyn Schlicher, PhD
Founding Head of Commercialisation
Launched Natera's flagship test Signatera · ex-Abbott
Michelle Roeding
Michelle Roeding
Regulatory Advisor
Former Senior Director of Regulatory Affairs, Natera

The future of biotech
starts here